GlassScriptPhysician profile
Terence L Angtuaco
NPI 1497790877
$12,143.77
in general payments reported to CMS, 2019-2025
36 companies · $2,753 in 2025
The $2,753 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $801 · 2021: $1,991 · 2022: $2,058 · 2023: $1,823 · 2024: $1,639 · 2025: $2,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,457 · Travel and Lodging: $704 · Education: $53.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,456.88 |
| Travel and Lodging | $704.09 |
| Education | $53.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,343.28 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Medtronic, INC. | $1,196.84 | 2024-2025 | Interstim |
| Gilead Sciences, INC. | $718.04 | 2020-2025 | |
| Janssen Biotech, INC. | $670.67 | 2020-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.64 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $451.79 | 2019-2025 | Entyvio |
| Pfizer INC. | $429.28 | 2019-2025 | |
| Genzyme Corporation | $414.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $320.12 | 2022-2025 | Dupixent |
| Celgene Corporation | $295.29 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $199.44 | 2021-2023 | |
| Redhill Biopharma INC. | $177.96 | 2021 | |
| Allergan, INC. | $147.21 | 2019 | |
| Kyowa Kirin, INC. | $144.63 | 2023 | Crysvita |
| Aimmune Therapeutics, INC. | $126.09 | 2024-2025 | Zenpep |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $107.68 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $106.30 | 2020-2024 | Dificid |
| Alexion Pharmaceuticals, INC. | $99.08 | 2019 | |
| Ardelyx, INC. | $89.77 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $83.22 | 2021-2022 | |
| Enterra Medical, INC. | $71.25 | 2022-2023 | |
| Lilly USA, LLC | $70.52 | 2023-2025 | Omvoh, Zepbound |
| Ipsen Biopharmaceuticals, INC | $53.45 | 2024-2025 | Iqirvo |
| Amgen INC. | $50.01 | 2020-2025 | Uplizna |
| Medtronic USA, INC. | $39.26 | 2020 | |
| Intercept Pharmaceuticals, INC. | $32.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $30.67 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $26.77 | 2019-2021 | |
| Madrigal Pharmaceuticals | $22.89 | 2025 | Rezdiffra |
| Covidien LP | $21.18 | 2019 | |
| Organon LLC | $17.30 | 2021-2024 | |
| Shire North American Group INC | $13.71 | 2019 | |
| Celltrion USA INC. | $13.60 | 2025 | Vegzelma |
| Olympus America INC. | $13.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.43 | 2022 | |
| Braintree Laboratories, INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terence Angtuaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.